DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced today that Presbia will be participating at the 30th Congress of Deutschsprachige Gesellschaft für Intraokularlinsen-Implantation, Interventionelle und Refraktive Chirurgie (DGII), to be held in Mannheim, Germany on February 11 through February 13, 2016. The DGII Congress is a gathering of experts presenting the newest scientific research and trends in the area of cataract and refractive surgery. Presbia board member Gerd U. Auffarth, M.D., Ph.D., F.E.B.O. will conduct a presentation at the Congress.
“We are currently launching commercially in South Korea, and Germany is an important market for Presbia’s expansion in the next year. The DGII Congress is an ideal forum to further showcase our innovative Presbia Microlens™ and also expand the awareness of our groundbreaking treatment for near-vision restoration for patients worldwide,” said Todd Cooper, President and CEO of Presbia.
Presbia’s new Business Development Director for Europe, Volkmar Nass, will be available for one-on-one meetings at the Congress.
Forward-Looking Statements
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties, including, but not limited to, the factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.
About Presbia
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.
